chow mein
Selected indexed studies
- Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. (Lancet, 2024) [PMID:38461843]
- "Chow mein" phytobezoar: the "surgical" Chinese restaurant syndrome. (Am Surg, 1973) [PMID:4698530]
- Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. (N Engl J Med, 2022) [PMID:35833805]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. (2024) pubmed
- "Chow mein" phytobezoar: the "surgical" Chinese restaurant syndrome. (1973) pubmed
- Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. (2022) pubmed
- Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trial. (2026) pubmed
- Microbiology of a major foodborne outbreak of gastroenteritis caused by Yersinia enterocolitica serogroup O:8. (1983) pubmed
- Epidemiologic investigation of a Yersinia camp outbreak linked to a food handler. (1984) pubmed
- Product formulation for ohmic heating: blanching as a pretreatment method to improve uniformity in heating of solid-liquid food mixtures. (2007) pubmed
- Genotype-phenotype correlation in a large population of muscular dystrophy patients with LAMA2 mutations. (2010) pubmed
- Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. (2023) pubmed
- SEPN1-related myopathies: clinical course in a large cohort of patients. (2011) pubmed